ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
Corcept announced that ESMO Rare Cancers published a peer-reviewed case report describing an approximately eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer.
Why it matters — The report highlights a prolonged response involving Corcept's relacorilant in an oncology case.